Aim of the Project:

ARTemis is a phase III, randomised trial to determine whether the addition to neo-adjuvant chemotherapy of an anti-angiogenic agent bevacizumab is more effective than standard chemotherapy alone in terms of short-term and long-term outcome in women presenting with HER2-negative early breast cancer.

Associated translational science will use prospective molecular profiling and candidate gene analysis on paraffin embedded and fresh tissue to define molecular predictors response / resistance to bevacizumab and chemotherapy. A quality of life sub-study will collect data critical to any future health technology assessment of bevacizumab in this indication.

Trial Summary

Current Trial Protocol V6.0

ARTemis Data Transparency Statement

Ethical Approval:

South East Research Ethics Committee

Project Schedule:

Start date: April 2009. Closed to recruitment: 09 January 2013. 800 patients recruited.

Sponsoring Institution:

Joint sponsorship - University of Cambridge and Cambridge University Hospitals NHS Foundation Trust

Lead Investigators:

Dr Jean Abraham - Cambridge	Chief Investigator
Dr Larry Hayward - Edinburgh	Deputy Chief Investigator
Professor Janet Dunn - Warwick	Trial Statistician

 

Key People

Dr Jean Abraham

Chief Investigator

Dr Larry Hayward

Deputy Chief Investigator

Professor Janet Dunn

Trial Statistician

 

Enquiries

 

Donna Howe

Trial Administrator (Warwick)

Artemis at warwick dot ac dot uk

Stanly Thomas

Clinical Trial Coordinator (Cambridge)